[Possibilities of the use of an inhibitor of hemolysis (AMCHA), by rectal and vaginal administration, for gynecological hemorrhages].
D000293:Adolescent; D000328:Adult; D000368:Aged; D001778:Blood Coagulation Disorders / Q000150:complications; D002648:Child; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D005260:Female; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D007889:Leiomyoma / Q000150:complications; D008595:Menorrhagia / Q000188:drug therapy; D008796:Metrorrhagia / Q000188:drug therapy; D008875:Middle Aged; D010923:Placenta Previa / Q000150:complications; D011183:Postoperative Complications; D011247:Pregnancy; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D014592:Uterine Hemorrhage / Q000188:drug therapy* / Q000209:etiology
D003509:Cyclohexanecarboxylic Acids; D014148:Tranexamic Acid
Considerazioni sulla possibilità d'impiego di un inhibitore della fibrinolisi (AMCA) per via rettale e per via vaginale nelle emorragie di interesse ginecologico